Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027 [Seeking Alpha]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Seeking Alpha
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025. PCVX's market potential is driven by a $13.3 billion TAM in the pneumococcal vaccine market, with potential FDA approval by late 2026 or 2027. PCVX's robust pipeline and potential FDA approvals, which could secure a dominant market position in a sizeable TAM, make it a “strong buy” for investors who understand the inherent biotech risks. MicroStockHub Vaxcyte, Inc. ( NASDAQ: PCVX ) is developing next-generation vaccines to prevent and treat bacterial infections through its novel Cell-Free Protein Synthesis [XpressCF] platform. PCVX's technology ov
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Alexandria Real Estate Equities, Inc. Announces Long-Term 258,581 RSF Lease With Longstanding Tenant Vaxcyte, Inc. at the Alexandria Center for Life Science - San Carlos Mega Campus [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult ProgramsGlobeNewswire
- 1 Vanguard ETF That Could Soar 27.1% Before the End of 2024, According to a Top Wall Street Analyst [Yahoo! Finance]Yahoo! Finance
- We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
PCVX
Earnings
- 11/5/24 - Beat
PCVX
Sec Filings
- 11/21/24 - Form 8-K
- 11/19/24 - Form 4
- 11/19/24 - Form 4
- PCVX's page on the SEC website